ProPhase Labs, Inc. (PRPH) 10-Year Financial Performance & Capital Metrics

PRPH • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareOTC Medications

AboutProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Show more

Revenue $7M -84.7%
EBITDA -$32M -114.4%
Net Income -$53M -218.0%
EPS (Diluted) -2.61 -166.3%
Gross Margin -2.22% -106.1%
EBITDA Margin -472.45% -1305.9%
Operating Margin -570.59% -1071.8%
Net Margin -788.24% -1984.7%
ROE -188.11% -533.4%
ROIC -59.44% -134.2%
Debt/Equity 3.34 +794.2%
Interest Coverage -11.53 +32.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.4x book value

✗Weaknesses

✗High debt to equity ratio of 3.3x
✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 7.3% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-11.15%

5Y-7.27%

3Y-55.92%

TTM-91.55%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-50.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM-8.61%

ROCE

10Y Avg-19.29%

5Y Avg-15.09%

3Y Avg-24.49%

Latest-75.64%

Peer Comparison

OTC Medications

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HLNHaleon plc	43.51B	9.77	30.53	-0.61%	11.72%	16.31%	4.71%	0.62
UPCUniverse Pharmaceuticals Inc.	2.59M	4.59	-0.00	-28.74%	-37.94%	-31.64%		0.18
PRPHProPhase Labs, Inc.	711.94K	0.17	-0.07	-84.75%	-38.72%	-6.08%		3.34
COSMCosmos Health Inc.	20.24M	0.54	-0.46	1.97%	-31.01%	-80.15%		0.48
PRGOPerrigo Company plc	2.09B	15.17	-12.14	-6.06%	-1.21%	-1.17%	11.72%	0.84

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.6M	21.01M	9.87M	13.13M	9.88M	14.51M	79.04M	122.65M	44.38M	6.77M
Revenue Growth %	-0.07%	0.02%	-0.53%	0.33%	-0.25%	0.47%	4.45%	0.55%	-0.64%	-0.85%
Cost of Goods Sold+	8.43M	10.95M	7.92M	8.35M	7.26M	9.91M	46.23M	51.99M	28.14M	6.92M
COGS % of Revenue	0.41%	0.52%	0.8%	0.64%	0.74%	0.68%	0.58%	0.42%	0.63%	1.02%
Gross Profit+	12.18M	10.07M	1.95M	4.78M	2.62M	4.61M	32.81M	70.65M	16.24M	-150K
Gross Margin %	0.59%	0.48%	0.2%	0.36%	0.26%	0.32%	0.42%	0.58%	0.37%	-0.02%
Gross Profit Growth %	-0.14%	-0.17%	-0.81%	1.45%	-0.45%	0.76%	6.12%	1.15%	-0.77%	-1.01%
Operating Expenses+	15.76M	12.72M	5.94M	6.42M	5.85M	8.58M	23.01M	47.06M	37.85M	38.48M
OpEx % of Revenue	0.76%	0.61%	0.6%	0.49%	0.59%	0.59%	0.29%	0.38%	0.85%	5.68%
Selling, General & Admin	14.68M	12.15M	5.51M	6.02M	5.52M	7.95M	22.49M	46.41M	34.5M	37.88M
SG&A % of Revenue	0.71%	0.58%	0.56%	0.46%	0.56%	0.55%	0.28%	0.38%	0.78%	5.6%
Research & Development	1.08M	575K	431K	398K	332K	633K	520K	652K	1.42M	594K
R&D % of Revenue	0.05%	0.03%	0.04%	0.03%	0.03%	0.04%	0.01%	0.01%	0.03%	0.09%
Other Operating Expenses	0	0	0	0	0	0	0	0	1.93M	0
Operating Income+	-3.58M	-2.66M	-3.99M	-1.63M	-3.24M	-3.97M	9.8M	23.59M	-21.61M	-38.63M
Operating Margin %	-0.17%	-0.13%	-0.4%	-0.12%	-0.33%	-0.27%	0.12%	0.19%	-0.49%	-5.71%
Operating Income Growth %	0.54%	0.26%	-0.5%	0.59%	-0.98%	-0.23%	3.47%	1.41%	-1.92%	-0.79%
EBITDA+	-3.22M	-2.31M	-3.65M	-1.25M	-2.84M	-3.44M	14.74M	28.66M	-14.91M	-31.98M
EBITDA Margin %	-0.16%	-0.11%	-0.37%	-0.1%	-0.29%	-0.24%	0.19%	0.23%	-0.34%	-4.72%
EBITDA Growth %	0.57%	0.28%	-0.58%	0.66%	-1.27%	-0.21%	5.28%	0.94%	-1.52%	-1.14%
D&A (Non-Cash Add-back)	367K	347K	337K	383K	398K	531K	4.93M	5.06M	6.7M	6.64M
EBIT	-2.08M	-3.79M	-3.99M	-1.63M	-3.11M	-2.02M	6.45M	23.67M	-21.52M	-38.98M
Net Interest Income+	-16K	-212K	177K	167K	133K	-233K	-506K	-611K	-1.2M	-3.35M
Interest Income	2K	1K	231K	167K	133K	62K	642K	153K	78K	0
Interest Expense	18K	213K	54K	0	0	295K	1.15M	764K	1.27M	3.35M
Other Income/Expense	-16K	-1.35M	327K	167K	133K	1.66M	-4.5M	-687K	-785K	-3.7M
Pretax Income+	-3.6M	-2.87M	-3.66M	-1.47M	-3.11M	-2.31M	5.3M	22.91M	-22.4M	-42.33M
Pretax Margin %	-0.17%	-0.14%	-0.37%	-0.11%	-0.31%	-0.16%	0.07%	0.19%	-0.5%	-6.25%
Income Tax+	16K	212K	-17.99M	103K	0	12K	-968K	4.45M	-6.02M	7.2M
Effective Tax Rate %	1%	1%	-11.42%	1.19%	1.01%	0.92%	1.18%	0.81%	0.75%	1.26%
Net Income+	-3.6M	-2.87M	41.83M	-1.74M	-3.15M	-2.13M	6.27M	18.46M	-16.78M	-53.36M
Net Margin %	-0.17%	-0.14%	4.24%	-0.13%	-0.32%	-0.15%	0.08%	0.15%	-0.38%	-7.88%
Net Income Growth %	0.54%	0.2%	15.59%	-1.04%	-0.81%	0.32%	3.95%	1.94%	-1.91%	-2.18%
Net Income (Continuing)	-2.09M	-4.01M	-2.24M	-1.57M	-3.11M	-2.33M	6.27M	18.46M	-16.38M	-49.52M
Discontinued Operations	0	0	0	0	0	201K	0	0	-402K	-3.84M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.22	-0.17	2.59	-0.15	-0.26	-0.20	0.40	1.02	-0.98	-2.61
EPS Growth %	0.53%	0.23%	16.24%	-1.06%	-0.73%	0.23%	3%	1.55%	-1.96%	-1.66%
EPS (Basic)	-0.22	-0.17	2.61	-0.15	-0.26	-0.20	0.41	1.17	-0.98	-2.61
Diluted Shares Outstanding	16.4M	17.08M	15.7M	11.4M	11.56M	11.6M	18.39M	18.65M	17.21M	19.08M
Basic Shares Outstanding	16.11M	16.69M	15.56M	11.4M	11.56M	11.6M	15.17M	15.85M	17.21M	19.08M
Dividend Payout Ratio	-	-	-	-	-	-	0.72%	0.51%	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.88M	9.63M	28.92M	18.24M	9.95M	15.89M	61.32M	60.83M	47.59M	30.64M
Cash & Short-Term Investments	1.66M	441K	21.94M	8.24M	1.36M	8.46M	17.51M	17.44M	4.74M	678K
Cash Only	1.66M	441K	3.17M	1.55M	434K	6.82M	8.66M	9.11M	1.61M	678K
Short-Term Investments	0	0	18.77M	6.69M	926K	1.64M	8.86M	8.33M	3.13M	0
Accounts Receivable	4M	5.77M	1.95M	7.8M	6.82M	3.15M	37.71M	37.05M	35.81M	20.06M
Days Sales Outstanding	70.86	100.22	71.95	216.84	252.13	79.34	174.13	110.27	294.52	1.08K
Inventory	4.33M	2.74M	1.53M	1.9M	1.46M	3.04M	4.6M	3.98M	2.29M	1.14M
Days Inventory Outstanding	187.61	91.22	70.57	83.23	73.34	111.95	36.32	27.91	29.71	60.29
Other Current Assets	1.88M	417K	2.86M	296K	304K	1.24M	1.5M	2.37M	4.74M	8.76M
Total Non-Current Assets+	2.95M	3.17M	5.24M	2.5M	2.33M	15.52M	27.98M	26.81M	44.34M	32.56M
Property, Plant & Equipment	2.95M	3.17M	2.74M	2.5M	2.33M	8.31M	10.35M	11.35M	14.9M	11.62M
Fixed Asset Turnover	6.98x	6.62x	3.60x	5.25x	4.24x	1.75x	7.64x	10.81x	2.98x	0.58x
Goodwill	0	0	0	0	0	901K	5.71M	5.71M	5.23M	5.23M
Intangible Assets	0	0	0	0	0	1.23M	10.85M	8.47M	12.33M	9.75M
Long-Term Investments	0	0	0	0	0	2.75M	0	0	0	0
Other Non-Current Assets	0	0	2.5M	0	0	2.32M	1.07M	1.28M	4.56M	5.97M
Total Assets+	14.83M	12.8M	34.16M	20.74M	12.27M	31.41M	89.3M	87.65M	91.93M	63.2M
Asset Turnover	1.39x	1.64x	0.29x	0.63x	0.80x	0.46x	0.89x	1.40x	0.48x	0.11x
Asset Growth %	-0.08%	-0.14%	1.67%	-0.39%	-0.41%	1.56%	1.84%	-0.02%	0.05%	-0.31%
Total Current Liabilities+	4.53M	6.84M	1.81M	4.23M	933K	6.29M	15.52M	16.07M	20.86M	32.13M
Accounts Payable	990K	2.16M	562K	437K	432K	3.77M	7.03M	5.91M	8.64M	13.72M
Days Payables Outstanding	42.89	71.88	25.9	19.11	21.72	138.92	55.47	41.45	112.1	723.51
Short-Term Debt	0	1.49M	0	0	0	329K	663K	301K	2.79M	6.57M
Deferred Revenue (Current)	0	0	0	206K	104K	169K	1000K	1000K	1000K	1000K
Other Current Liabilities	3.06M	3.02M	1.25M	3.2M	310K	1.52M	3.92M	2.93M	2.6M	8.03M
Current Ratio	2.62x	1.41x	15.96x	4.31x	10.66x	2.52x	3.95x	3.78x	2.28x	0.95x
Quick Ratio	1.66x	1.01x	15.11x	3.86x	9.10x	2.04x	3.65x	3.54x	2.17x	0.92x
Cash Conversion Cycle	215.59	119.56	116.61	280.96	303.76	52.38	154.97	96.73	212.13	418.19
Total Non-Current Liabilities+	1.47M	0	0	0	110K	14.55M	15.14M	7.94M	21.69M	23.71M
Long-Term Debt	1.47M	0	0	0	0	9.99M	10.04M	2.4M	7.33M	11.65M
Capital Lease Obligations	0	0	0	0	0	4.4M	4.2M	4.26M	8.33M	6.35M
Deferred Tax Liabilities	0	0	0	0	0	0	0	224K	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	4.92M	4.92M
Total Liabilities	6M	6.84M	1.07M	4.23M	1.04M	20.85M	30.67M	24.02M	42.54M	55.85M
Total Debt+	1.47M	1.49M	0	0	0	14.72M	14.9M	6.96M	18.46M	24.57M
Net Debt	-198K	1.05M	-3.17M	-1.55M	-434K	7.91M	6.24M	-2.15M	16.85M	23.89M
Debt / Equity	0.17x	0.25x	-	-	-	1.39x	0.25x	0.11x	0.37x	3.34x
Debt / EBITDA	-	-	-	-	-	-	1.01x	0.24x	-	-
Net Debt / EBITDA	-	-	-	-	-	-	0.42x	-0.07x	-	-
Interest Coverage	-199.11x	-12.47x	-73.89x	-	-	-13.47x	8.54x	30.88x	-16.95x	-11.53x
Total Equity+	8.83M	5.96M	31.85M	16.5M	11.23M	10.56M	58.63M	63.63M	49.38M	7.35M
Equity Growth %	-0.18%	-0.32%	4.34%	-0.48%	-0.32%	-0.06%	4.55%	0.09%	-0.22%	-0.85%
Book Value per Share	0.54	0.35	2.03	1.45	0.97	0.91	3.19	3.41	2.87	0.39
Total Shareholders' Equity	8.83M	5.96M	31.85M	16.5M	11.23M	10.56M	58.63M	63.63M	49.38M	7.35M
Common Stock	13K	13K	14K	14K	14K	14K	16K	16K	18K	23K
Retained Earnings	-16.82M	-19.69M	22.14M	4.53M	-1.51M	-3.63M	2.64M	11.75M	-5.03M	-58.39M
Treasury Stock	-30.74M	-30.74M	-47.02M	-47.49M	-47.49M	-47.49M	-48.41M	-58.03M	-64M	-64M
Accumulated OCI	-4.71M	-5.13M	-78K	-24K	-2K	-11K	-175K	757K	-300K	-198K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.5M	-472K	-2.84M	-2.12M	-841K	-2.59M	-13.62M	28.55M	-11.35M	-17.54M
Operating CF Margin %	-0.17%	-0.02%	-0.29%	-0.16%	-0.09%	-0.18%	-0.17%	0.23%	-0.26%	-2.59%
Operating CF Growth %	-0.09%	0.87%	-5.01%	0.25%	0.6%	-2.08%	-4.25%	3.1%	-1.4%	-0.55%
Net Income	-3.6M	-2.87M	41.83M	-1.74M	-3.15M	-2.13M	6.27M	18.46M	-16.78M	-49.52M
Depreciation & Amortization	367K	426K	337K	383K	398K	458K	3.56M	5.06M	6.7M	6.64M
Stock-Based Compensation	135K	1K	78K	634K	744K	1.46M	3.18M	3.99M	3.54M	3.64M
Deferred Taxes	-144K	0	-17.99M	130K	12K	-1.89M	557K	-138K	0	7.15M
Other Non-Cash Items	135K	24K	-26.67M	170K	40K	118K	-311K	5.52M	896K	-334K
Working Capital Changes	-390K	1.95M	-421K	-1.7M	1.11M	-608K	-26.88M	-4.34M	-5.7M	14.89M
Change in Receivables	1.84M	-1.77M	3.83M	-1.02M	936K	-1.04M	-30.47M	-4.5M	718K	4.74M
Change in Inventory	-1.04M	1.59M	1.21M	-372K	444K	-1.47M	-1.75M	702K	135K	1.36M
Change in Payables	323K	1.17M	-1.59M	-125K	-14K	3.34M	2.45M	-1.12M	3.48M	5.07M
Cash from Investing+	-709K	-651K	21.77M	11.86M	5.54M	-1.02M	-19.67M	-2.08M	-1.37M	2.42M
Capital Expenditures	-718K	-651K	-208K	-140K	-228K	-1.69M	-4.23M	-3.92M	-3.15M	-906K
CapEx % of Revenue	0.03%	0.03%	0.02%	0.01%	0.02%	0.12%	0.05%	0.03%	0.07%	0.13%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9K	-651K	40.83M	-139K	-228K	3.89M	-700K	0	524K	-46K
Cash from Financing+	2.94M	-100K	-16.2M	-11.36M	-5.82M	9.99M	35.13M	-26.02M	5.76M	14.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-11.7M	-5.82M	0	-4.55M	-9.35M	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-20K	0	1.58M	338K	0	-10K	0	-7.47M	1.2M	978K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.21M	-1.12M	-3.05M	-2.26M	-1.07M	-4.28M	-17.85M	24.63M	-14.5M	-18.44M
FCF Margin %	-0.2%	-0.05%	-0.31%	-0.17%	-0.11%	-0.29%	-0.23%	0.2%	-0.33%	-2.72%
FCF Growth %	-0.19%	0.73%	-1.71%	0.26%	0.53%	-3%	-3.17%	2.38%	-1.59%	-0.27%
FCF per Share	-0.26	-0.07	-0.19	-0.20	-0.09	-0.37	-0.97	1.32	-0.84	-0.97
FCF Conversion (FCF/Net Income)	0.97x	0.16x	-0.07x	1.22x	0.27x	1.22x	-2.17x	1.55x	0.68x	0.33x
Interest Paid	0	0	54K	0	0	0	0	763K	932K	3.1M
Taxes Paid	0	0	1.35M	0	103K	0	0	1.7M	3M	1.13M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-36.84%	-38.78%	221.28%	-7.2%	-22.69%	-19.51%	18.13%	30.2%	-29.7%	-188.11%
Return on Invested Capital (ROIC)	-32.74%	-25.47%	-16.77%	-5.62%	-18.87%	-20.37%	17.64%	28.01%	-25.38%	-59.44%
Gross Margin	59.1%	47.9%	19.74%	36.42%	26.48%	31.73%	41.51%	57.61%	36.59%	-2.22%
Net Margin	-17.47%	-13.65%	423.95%	-13.26%	-31.86%	-14.64%	7.94%	15.05%	-37.81%	-788.24%
Debt / Equity	0.17x	0.25x	-	-	-	1.39x	0.25x	0.11x	0.37x	3.34x
Interest Coverage	-199.11x	-12.47x	-73.89x	-	-	-13.47x	8.54x	30.88x	-16.95x	-11.53x
FCF Conversion	0.97x	0.16x	-0.07x	1.22x	0.27x	1.22x	-2.17x	1.55x	0.68x	0.33x
Revenue Growth	-6.64%	1.99%	-53.05%	33.03%	-24.76%	46.96%	444.59%	55.17%	-63.81%	-84.75%

Revenue by Segment

	2021	2022	2023	2024
Consumer Products	10.48M	14.32M	19.54M	6.77M
Consumer Products Growth	-	36.58%	36.44%	-65.34%
Diagnostic Services	68.56M	108.33M	24.85M	-
Diagnostic Services Growth	-	58.01%	-77.06%	-

Frequently Asked Questions

Growth & Financials

ProPhase Labs, Inc. (PRPH) reported $1.1M in revenue for fiscal year 2024. This represents a 94% decrease from $17.5M in 2011.

ProPhase Labs, Inc. (PRPH) saw revenue decline by 84.7% over the past year.

ProPhase Labs, Inc. (PRPH) reported a net loss of $41.7M for fiscal year 2024.

Dividend & Returns

ProPhase Labs, Inc. (PRPH) has a return on equity (ROE) of -188.1%. Negative ROE indicates the company is unprofitable.

ProPhase Labs, Inc. (PRPH) had negative free cash flow of $22.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

ProPhase Labs, Inc. (PRPH) 10-Year Financial Performance & Capital Metrics

PRPH • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareOTC Medications

Revenue $7M -84.7%
EBITDA -$32M -114.4%
Net Income -$53M -218.0%
EPS (Diluted) -2.61 -166.3%
Gross Margin -2.22% -106.1%
EBITDA Margin -472.45% -1305.9%
Operating Margin -570.59% -1071.8%
Net Margin -788.24% -1984.7%
ROE -188.11% -533.4%
ROIC -59.44% -134.2%
Debt/Equity 3.34 +794.2%
Interest Coverage -11.53 +32.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.4x book value

✗Weaknesses

✗High debt to equity ratio of 3.3x
✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 7.3% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-11.15%

5Y-7.27%

3Y-55.92%

TTM-91.55%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-50.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM-8.61%

ROCE

10Y Avg-19.29%

5Y Avg-15.09%

3Y Avg-24.49%

Latest-75.64%

Peer Comparison

OTC Medications

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HLNHaleon plc	43.51B	9.77	30.53	-0.61%	11.72%	16.31%	4.71%	0.62
UPCUniverse Pharmaceuticals Inc.	2.59M	4.59	-0.00	-28.74%	-37.94%	-31.64%		0.18
PRPHProPhase Labs, Inc.	711.94K	0.17	-0.07	-84.75%	-38.72%	-6.08%		3.34
COSMCosmos Health Inc.	20.24M	0.54	-0.46	1.97%	-31.01%	-80.15%		0.48
PRGOPerrigo Company plc	2.09B	15.17	-12.14	-6.06%	-1.21%	-1.17%	11.72%	0.84

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.6M	21.01M	9.87M	13.13M	9.88M	14.51M	79.04M	122.65M	44.38M	6.77M
Revenue Growth %	-0.07%	0.02%	-0.53%	0.33%	-0.25%	0.47%	4.45%	0.55%	-0.64%	-0.85%
Cost of Goods Sold+	8.43M	10.95M	7.92M	8.35M	7.26M	9.91M	46.23M	51.99M	28.14M	6.92M
COGS % of Revenue	0.41%	0.52%	0.8%	0.64%	0.74%	0.68%	0.58%	0.42%	0.63%	1.02%
Gross Profit+	12.18M	10.07M	1.95M	4.78M	2.62M	4.61M	32.81M	70.65M	16.24M	-150K
Gross Margin %	0.59%	0.48%	0.2%	0.36%	0.26%	0.32%	0.42%	0.58%	0.37%	-0.02%
Gross Profit Growth %	-0.14%	-0.17%	-0.81%	1.45%	-0.45%	0.76%	6.12%	1.15%	-0.77%	-1.01%
Operating Expenses+	15.76M	12.72M	5.94M	6.42M	5.85M	8.58M	23.01M	47.06M	37.85M	38.48M
OpEx % of Revenue	0.76%	0.61%	0.6%	0.49%	0.59%	0.59%	0.29%	0.38%	0.85%	5.68%
Selling, General & Admin	14.68M	12.15M	5.51M	6.02M	5.52M	7.95M	22.49M	46.41M	34.5M	37.88M
SG&A % of Revenue	0.71%	0.58%	0.56%	0.46%	0.56%	0.55%	0.28%	0.38%	0.78%	5.6%
Research & Development	1.08M	575K	431K	398K	332K	633K	520K	652K	1.42M	594K
R&D % of Revenue	0.05%	0.03%	0.04%	0.03%	0.03%	0.04%	0.01%	0.01%	0.03%	0.09%
Other Operating Expenses	0	0	0	0	0	0	0	0	1.93M	0
Operating Income+	-3.58M	-2.66M	-3.99M	-1.63M	-3.24M	-3.97M	9.8M	23.59M	-21.61M	-38.63M
Operating Margin %	-0.17%	-0.13%	-0.4%	-0.12%	-0.33%	-0.27%	0.12%	0.19%	-0.49%	-5.71%
Operating Income Growth %	0.54%	0.26%	-0.5%	0.59%	-0.98%	-0.23%	3.47%	1.41%	-1.92%	-0.79%
EBITDA+	-3.22M	-2.31M	-3.65M	-1.25M	-2.84M	-3.44M	14.74M	28.66M	-14.91M	-31.98M
EBITDA Margin %	-0.16%	-0.11%	-0.37%	-0.1%	-0.29%	-0.24%	0.19%	0.23%	-0.34%	-4.72%
EBITDA Growth %	0.57%	0.28%	-0.58%	0.66%	-1.27%	-0.21%	5.28%	0.94%	-1.52%	-1.14%
D&A (Non-Cash Add-back)	367K	347K	337K	383K	398K	531K	4.93M	5.06M	6.7M	6.64M
EBIT	-2.08M	-3.79M	-3.99M	-1.63M	-3.11M	-2.02M	6.45M	23.67M	-21.52M	-38.98M
Net Interest Income+	-16K	-212K	177K	167K	133K	-233K	-506K	-611K	-1.2M	-3.35M
Interest Income	2K	1K	231K	167K	133K	62K	642K	153K	78K	0
Interest Expense	18K	213K	54K	0	0	295K	1.15M	764K	1.27M	3.35M
Other Income/Expense	-16K	-1.35M	327K	167K	133K	1.66M	-4.5M	-687K	-785K	-3.7M
Pretax Income+	-3.6M	-2.87M	-3.66M	-1.47M	-3.11M	-2.31M	5.3M	22.91M	-22.4M	-42.33M
Pretax Margin %	-0.17%	-0.14%	-0.37%	-0.11%	-0.31%	-0.16%	0.07%	0.19%	-0.5%	-6.25%
Income Tax+	16K	212K	-17.99M	103K	0	12K	-968K	4.45M	-6.02M	7.2M
Effective Tax Rate %	1%	1%	-11.42%	1.19%	1.01%	0.92%	1.18%	0.81%	0.75%	1.26%
Net Income+	-3.6M	-2.87M	41.83M	-1.74M	-3.15M	-2.13M	6.27M	18.46M	-16.78M	-53.36M
Net Margin %	-0.17%	-0.14%	4.24%	-0.13%	-0.32%	-0.15%	0.08%	0.15%	-0.38%	-7.88%
Net Income Growth %	0.54%	0.2%	15.59%	-1.04%	-0.81%	0.32%	3.95%	1.94%	-1.91%	-2.18%
Net Income (Continuing)	-2.09M	-4.01M	-2.24M	-1.57M	-3.11M	-2.33M	6.27M	18.46M	-16.38M	-49.52M
Discontinued Operations	0	0	0	0	0	201K	0	0	-402K	-3.84M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.22	-0.17	2.59	-0.15	-0.26	-0.20	0.40	1.02	-0.98	-2.61
EPS Growth %	0.53%	0.23%	16.24%	-1.06%	-0.73%	0.23%	3%	1.55%	-1.96%	-1.66%
EPS (Basic)	-0.22	-0.17	2.61	-0.15	-0.26	-0.20	0.41	1.17	-0.98	-2.61
Diluted Shares Outstanding	16.4M	17.08M	15.7M	11.4M	11.56M	11.6M	18.39M	18.65M	17.21M	19.08M
Basic Shares Outstanding	16.11M	16.69M	15.56M	11.4M	11.56M	11.6M	15.17M	15.85M	17.21M	19.08M
Dividend Payout Ratio	-	-	-	-	-	-	0.72%	0.51%	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.88M	9.63M	28.92M	18.24M	9.95M	15.89M	61.32M	60.83M	47.59M	30.64M
Cash & Short-Term Investments	1.66M	441K	21.94M	8.24M	1.36M	8.46M	17.51M	17.44M	4.74M	678K
Cash Only	1.66M	441K	3.17M	1.55M	434K	6.82M	8.66M	9.11M	1.61M	678K
Short-Term Investments	0	0	18.77M	6.69M	926K	1.64M	8.86M	8.33M	3.13M	0
Accounts Receivable	4M	5.77M	1.95M	7.8M	6.82M	3.15M	37.71M	37.05M	35.81M	20.06M
Days Sales Outstanding	70.86	100.22	71.95	216.84	252.13	79.34	174.13	110.27	294.52	1.08K
Inventory	4.33M	2.74M	1.53M	1.9M	1.46M	3.04M	4.6M	3.98M	2.29M	1.14M
Days Inventory Outstanding	187.61	91.22	70.57	83.23	73.34	111.95	36.32	27.91	29.71	60.29
Other Current Assets	1.88M	417K	2.86M	296K	304K	1.24M	1.5M	2.37M	4.74M	8.76M
Total Non-Current Assets+	2.95M	3.17M	5.24M	2.5M	2.33M	15.52M	27.98M	26.81M	44.34M	32.56M
Property, Plant & Equipment	2.95M	3.17M	2.74M	2.5M	2.33M	8.31M	10.35M	11.35M	14.9M	11.62M
Fixed Asset Turnover	6.98x	6.62x	3.60x	5.25x	4.24x	1.75x	7.64x	10.81x	2.98x	0.58x
Goodwill	0	0	0	0	0	901K	5.71M	5.71M	5.23M	5.23M
Intangible Assets	0	0	0	0	0	1.23M	10.85M	8.47M	12.33M	9.75M
Long-Term Investments	0	0	0	0	0	2.75M	0	0	0	0
Other Non-Current Assets	0	0	2.5M	0	0	2.32M	1.07M	1.28M	4.56M	5.97M
Total Assets+	14.83M	12.8M	34.16M	20.74M	12.27M	31.41M	89.3M	87.65M	91.93M	63.2M
Asset Turnover	1.39x	1.64x	0.29x	0.63x	0.80x	0.46x	0.89x	1.40x	0.48x	0.11x
Asset Growth %	-0.08%	-0.14%	1.67%	-0.39%	-0.41%	1.56%	1.84%	-0.02%	0.05%	-0.31%
Total Current Liabilities+	4.53M	6.84M	1.81M	4.23M	933K	6.29M	15.52M	16.07M	20.86M	32.13M
Accounts Payable	990K	2.16M	562K	437K	432K	3.77M	7.03M	5.91M	8.64M	13.72M
Days Payables Outstanding	42.89	71.88	25.9	19.11	21.72	138.92	55.47	41.45	112.1	723.51
Short-Term Debt	0	1.49M	0	0	0	329K	663K	301K	2.79M	6.57M
Deferred Revenue (Current)	0	0	0	206K	104K	169K	1000K	1000K	1000K	1000K
Other Current Liabilities	3.06M	3.02M	1.25M	3.2M	310K	1.52M	3.92M	2.93M	2.6M	8.03M
Current Ratio	2.62x	1.41x	15.96x	4.31x	10.66x	2.52x	3.95x	3.78x	2.28x	0.95x
Quick Ratio	1.66x	1.01x	15.11x	3.86x	9.10x	2.04x	3.65x	3.54x	2.17x	0.92x
Cash Conversion Cycle	215.59	119.56	116.61	280.96	303.76	52.38	154.97	96.73	212.13	418.19
Total Non-Current Liabilities+	1.47M	0	0	0	110K	14.55M	15.14M	7.94M	21.69M	23.71M
Long-Term Debt	1.47M	0	0	0	0	9.99M	10.04M	2.4M	7.33M	11.65M
Capital Lease Obligations	0	0	0	0	0	4.4M	4.2M	4.26M	8.33M	6.35M
Deferred Tax Liabilities	0	0	0	0	0	0	0	224K	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	4.92M	4.92M
Total Liabilities	6M	6.84M	1.07M	4.23M	1.04M	20.85M	30.67M	24.02M	42.54M	55.85M
Total Debt+	1.47M	1.49M	0	0	0	14.72M	14.9M	6.96M	18.46M	24.57M
Net Debt	-198K	1.05M	-3.17M	-1.55M	-434K	7.91M	6.24M	-2.15M	16.85M	23.89M
Debt / Equity	0.17x	0.25x	-	-	-	1.39x	0.25x	0.11x	0.37x	3.34x
Debt / EBITDA	-	-	-	-	-	-	1.01x	0.24x	-	-
Net Debt / EBITDA	-	-	-	-	-	-	0.42x	-0.07x	-	-
Interest Coverage	-199.11x	-12.47x	-73.89x	-	-	-13.47x	8.54x	30.88x	-16.95x	-11.53x
Total Equity+	8.83M	5.96M	31.85M	16.5M	11.23M	10.56M	58.63M	63.63M	49.38M	7.35M
Equity Growth %	-0.18%	-0.32%	4.34%	-0.48%	-0.32%	-0.06%	4.55%	0.09%	-0.22%	-0.85%
Book Value per Share	0.54	0.35	2.03	1.45	0.97	0.91	3.19	3.41	2.87	0.39
Total Shareholders' Equity	8.83M	5.96M	31.85M	16.5M	11.23M	10.56M	58.63M	63.63M	49.38M	7.35M
Common Stock	13K	13K	14K	14K	14K	14K	16K	16K	18K	23K
Retained Earnings	-16.82M	-19.69M	22.14M	4.53M	-1.51M	-3.63M	2.64M	11.75M	-5.03M	-58.39M
Treasury Stock	-30.74M	-30.74M	-47.02M	-47.49M	-47.49M	-47.49M	-48.41M	-58.03M	-64M	-64M
Accumulated OCI	-4.71M	-5.13M	-78K	-24K	-2K	-11K	-175K	757K	-300K	-198K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.5M	-472K	-2.84M	-2.12M	-841K	-2.59M	-13.62M	28.55M	-11.35M	-17.54M
Operating CF Margin %	-0.17%	-0.02%	-0.29%	-0.16%	-0.09%	-0.18%	-0.17%	0.23%	-0.26%	-2.59%
Operating CF Growth %	-0.09%	0.87%	-5.01%	0.25%	0.6%	-2.08%	-4.25%	3.1%	-1.4%	-0.55%
Net Income	-3.6M	-2.87M	41.83M	-1.74M	-3.15M	-2.13M	6.27M	18.46M	-16.78M	-49.52M
Depreciation & Amortization	367K	426K	337K	383K	398K	458K	3.56M	5.06M	6.7M	6.64M
Stock-Based Compensation	135K	1K	78K	634K	744K	1.46M	3.18M	3.99M	3.54M	3.64M
Deferred Taxes	-144K	0	-17.99M	130K	12K	-1.89M	557K	-138K	0	7.15M
Other Non-Cash Items	135K	24K	-26.67M	170K	40K	118K	-311K	5.52M	896K	-334K
Working Capital Changes	-390K	1.95M	-421K	-1.7M	1.11M	-608K	-26.88M	-4.34M	-5.7M	14.89M
Change in Receivables	1.84M	-1.77M	3.83M	-1.02M	936K	-1.04M	-30.47M	-4.5M	718K	4.74M
Change in Inventory	-1.04M	1.59M	1.21M	-372K	444K	-1.47M	-1.75M	702K	135K	1.36M
Change in Payables	323K	1.17M	-1.59M	-125K	-14K	3.34M	2.45M	-1.12M	3.48M	5.07M
Cash from Investing+	-709K	-651K	21.77M	11.86M	5.54M	-1.02M	-19.67M	-2.08M	-1.37M	2.42M
Capital Expenditures	-718K	-651K	-208K	-140K	-228K	-1.69M	-4.23M	-3.92M	-3.15M	-906K
CapEx % of Revenue	0.03%	0.03%	0.02%	0.01%	0.02%	0.12%	0.05%	0.03%	0.07%	0.13%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	9K	-651K	40.83M	-139K	-228K	3.89M	-700K	0	524K	-46K
Cash from Financing+	2.94M	-100K	-16.2M	-11.36M	-5.82M	9.99M	35.13M	-26.02M	5.76M	14.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-11.7M	-5.82M	0	-4.55M	-9.35M	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-20K	0	1.58M	338K	0	-10K	0	-7.47M	1.2M	978K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.21M	-1.12M	-3.05M	-2.26M	-1.07M	-4.28M	-17.85M	24.63M	-14.5M	-18.44M
FCF Margin %	-0.2%	-0.05%	-0.31%	-0.17%	-0.11%	-0.29%	-0.23%	0.2%	-0.33%	-2.72%
FCF Growth %	-0.19%	0.73%	-1.71%	0.26%	0.53%	-3%	-3.17%	2.38%	-1.59%	-0.27%
FCF per Share	-0.26	-0.07	-0.19	-0.20	-0.09	-0.37	-0.97	1.32	-0.84	-0.97
FCF Conversion (FCF/Net Income)	0.97x	0.16x	-0.07x	1.22x	0.27x	1.22x	-2.17x	1.55x	0.68x	0.33x
Interest Paid	0	0	54K	0	0	0	0	763K	932K	3.1M
Taxes Paid	0	0	1.35M	0	103K	0	0	1.7M	3M	1.13M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-36.84%	-38.78%	221.28%	-7.2%	-22.69%	-19.51%	18.13%	30.2%	-29.7%	-188.11%
Return on Invested Capital (ROIC)	-32.74%	-25.47%	-16.77%	-5.62%	-18.87%	-20.37%	17.64%	28.01%	-25.38%	-59.44%
Gross Margin	59.1%	47.9%	19.74%	36.42%	26.48%	31.73%	41.51%	57.61%	36.59%	-2.22%
Net Margin	-17.47%	-13.65%	423.95%	-13.26%	-31.86%	-14.64%	7.94%	15.05%	-37.81%	-788.24%
Debt / Equity	0.17x	0.25x	-	-	-	1.39x	0.25x	0.11x	0.37x	3.34x
Interest Coverage	-199.11x	-12.47x	-73.89x	-	-	-13.47x	8.54x	30.88x	-16.95x	-11.53x
FCF Conversion	0.97x	0.16x	-0.07x	1.22x	0.27x	1.22x	-2.17x	1.55x	0.68x	0.33x
Revenue Growth	-6.64%	1.99%	-53.05%	33.03%	-24.76%	46.96%	444.59%	55.17%	-63.81%	-84.75%

Revenue by Segment

	2021	2022	2023	2024
Consumer Products	10.48M	14.32M	19.54M	6.77M
Consumer Products Growth	-	36.58%	36.44%	-65.34%
Diagnostic Services	68.56M	108.33M	24.85M	-
Diagnostic Services Growth	-	58.01%	-77.06%	-

Frequently Asked Questions

Growth & Financials

ProPhase Labs, Inc. (PRPH) reported $1.1M in revenue for fiscal year 2024. This represents a 94% decrease from $17.5M in 2011.

ProPhase Labs, Inc. (PRPH) saw revenue decline by 84.7% over the past year.

ProPhase Labs, Inc. (PRPH) reported a net loss of $41.7M for fiscal year 2024.

Dividend & Returns

ProPhase Labs, Inc. (PRPH) has a return on equity (ROE) of -188.1%. Negative ROE indicates the company is unprofitable.

ProPhase Labs, Inc. (PRPH) had negative free cash flow of $22.8M in fiscal year 2024, likely due to heavy capital investments.